A detailed history of Stonegate Investment Group, LLC transactions in In8 Bio, Inc. stock. As of the latest transaction made, Stonegate Investment Group, LLC holds 180,000 shares of INAB stock, worth $45,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
180,000
Previous 180,000 -0.0%
Holding current value
$45,000
Previous $153,000 68.63%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 26, 2023

SELL
$1.05 - $3.24 $54,925 - $169,484
-52,310 Reduced 22.52%
180,000 $277,000
Q3 2022

Oct 28, 2022

SELL
$1.77 - $2.89 $60,516 - $98,809
-34,190 Reduced 12.83%
232,310 $469,000
Q2 2022

Aug 09, 2022

BUY
$2.02 - $4.68 $538,330 - $1.25 Million
266,500 New
266,500 $602,000

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $6.13M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Stonegate Investment Group, LLC Portfolio

Follow Stonegate Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonegate Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonegate Investment Group, LLC with notifications on news.